FREE TRANSLATION NYRSTAR NV



Vergelijkbare documenten
Document subtitle= Verdana Heading 12 0/0 single. Option NV

ABLYNX NV. (de Vennootschap of Ablynx )

VERSLAG VAN DE COMMISSARIS R0401 UITGIFTE VAN WARRANTS MET OPHEFFING VAN HET VOORKEURRECHT

VOORSTEL TOT STATUTENWIJZIGING UNIQURE NV. Voorgesteld wordt om de artikelen 7.7.1, 8.6.1, en te wijzigen als volgt: Toelichting:

ABLYNX NV. (de Vennootschap of Ablynx )

STEMMING PER BRIEF VOTE BY MAIL. Buitengewone Algemene Aandeelhoudersvergadering Extraordinary General Shareholders Meeting

ABLYNX NV. (de Vennootschap of Ablynx )

THROMBOGENICS. (de Vennootschap ) VOLMACHT

TOELICHTING OP FUSIEVOORSTEL/

Inhoud Deze pdf bevat de volgende Engelstalige voorbeeldrapportages van sectie II, deel 3 HRA:

Volmacht Aandeelhouder Proxy Shareholder

Volmacht Aandeelhouder Proxy Shareholder

Nieuwe product naam: RELX ISIN code: NL Euronext code: NL Nieuwe symbool: RELX

TRYPTICH PROPOSED AMENDMENT TO THE ARTICLES OF ASSOCIATION ("AMENDMENT 2") ALTICE N.V.

Kapitaalverhoging met voorkeurrecht tot inschrijving WERELDHAVE N.V.

MyDHL+ Van Non-Corporate naar Corporate

VAN LANSCHOT N.V. DATUM: 11/03/2015 EURONEXT AMSTERDAM. Assimilation of Structured Note

ABLYNX NV. (de Vennootschap of Ablynx )

THROMBOGENICS. (de Vennootschap ) VOLMACHT

Full disclosure clausule in de overnameovereenkomst. International Law Firm Amsterdam Brussels London Luxembourg New York Rotterdam

OPTION NAAMLOZE VENNOOTSCHAP GASTON GEENSLAAN HEVERLEE BTW BE RPR LEUVEN

GOVERNMENT NOTICE. STAATSKOERANT, 18 AUGUSTUS 2017 No NATIONAL TREASURY. National Treasury/ Nasionale Tesourie NO AUGUST

Handleiding Regelgeving Accountancy. Engelstalige voorbeeldteksten

ABLYNX NV. (de Vennootschap of Ablynx )

Handleiding Regelgeving Accountancy. Engelstalige voorbeeldteksten

Volmacht / Stemformulier Proxy Form / Voting Form

Brexit en Wisselkoersrisico s. Wim De Boe FX Corporate Sales

VOLMACHT - POWER OF ATTORNEY

ABLYNX NV. (de Vennootschap of Ablynx )

MyDHL+ Uw accountnummer(s) delen

Volmacht / Stemformulier Proxy Form / Voting Form

OXURION. (de Vennootschap ) VOLMACHT

Volmacht Aandeelhouder Proxy Shareholder [NAAM AANDEELHOUDER] [NAME SHAREHOLDER],

VOLMACHT - POWER OF ATTORNEY

OCI N.V. De wijziging van valuta van USD naar EUR op Euronext Amsterdam zal per 28/08/2013 effectief zijn.

THROMBOGENICS. (de Vennootschap ) VOLMACHT

ABLYNX NV. (de Vennootschap of Ablynx )

Verslag van de commissaris over het voorstel van opheffing van het voorkeurrecht (art. 596 van het Wetboek van Vennootschappen) in Fagron NV

Euronext informs the members that the timetable of the corporate event will be as follows:

THROMBOGENICS. (de Vennootschap ) VOLMACHT

U I T S P R A A K

Resultaten Derde Kwartaal oktober 2015

Volmacht Aandeelhouder Proxy Shareholder [NAAM AANDEELHOUDER] [NAME SHAREHOLDER],

Report on the annual accounts - Unqualified opinion

Balansgaranties. Bart Bellen 5 oktober Minervastraat 5, 1930 Zaventem, T +32 (0) , F +32 (0) ,

fjr/cewaierhouse(ajpers I

THE ROYAL BANK OF SCOTLAND PLC heeft besloten tot een reverse split van haar aandelen nominaal 0.25 GBP in 2.50 GBP

THROMBOGENICS. (de Vennootschap ) VOLMACHT

ABLYNX NV. (de Vennootschap of Ablynx )

Antonov plc. Hoofdpunten:

VOLMACHT POWER OF ATTORNEY

THROMBOGENICS Naamloze Vennootschap die een openbaar beroep op het spaarwezen doet Gaston Geenslaan Heverlee

Inhoud Deze PDF bevat de drukproef van de volgende Engelstalige voorbeeldrapportages uit HRA dele 3:

BUITENGEWONE ALGEMENE VERGADERING VAN AANDEELHOUDERS 15 mei 2018 VOLMACHT EXTRAORDINARY SHAREHOLDERS MEETING 15 May 2018 STANDARD PROXY FORM

ABLYNX NV. (de Vennootschap of Ablynx )

THROMBOGENICS. (de Vennootschap ) VOLMACHT

VOLMACHT - POWER OF ATTORNEY

THROMBOGENICS. (de Vennootschap ) VOLMACHT

ABLYNX NV. (de Vennootschap of Ablynx )

THROMBOGENICS Naamloze Vennootschap die een openbaar beroep op het spaarwezen doet Gaston Geenslaan Heverlee

pwc UMICORE SA/NV Statutory auditor's report to the general shareholders' meeting on the annual accounts as of and for the year ended 31 December 2012

RECEPTEERKUNDE: PRODUCTZORG EN BEREIDING VAN GENEESMIDDELEN (DUTCH EDITION) FROM BOHN STAFLEU VAN LOGHUM

DEMERGER PROPOSAL (VOORSTEL TOT AFSPLITSING) with (met) ProQR Therapeutics N.V. as Demerging Company (als Splitsende Vennootschap) and (en)

Implementatiewet Europees kader voor herstel en afwikkeling van banken en beleggingsondernemingen (34 208) het "Wetsvoorstel"

BESLUIT TOT WIJZIGING VAN DE VOORWAARDEN VAN BEHEER EN BEWARING DELTA LLOYD FIXED INCOME UMBRELLA

POWER OF ATTORNEY FOR THE EXTRAORDINARY GENERAL SHAREHOLDERS MEETING OF SEPTEMBER 9, 2009

VOLMACHT - POWER OF ATTORNEY

CORPORATE EVENT NOTICE: KIADIS PHARMA NV AMS_ _04567_EUR DATUM: 01/07/2015 EURONEXT AMSTERDAM. Following AMS_ _04212_EUR

VOORGESTELDE WIJZIGING STATUTEN ALTICE N.V.

Volmacht / Stemformulier Proxy Form / Voting Form

VOLMACHT STANDARD PROXY FORM. Jaarlijkse algemene vergadering van 21 mei 2013 te Antwerpen Ordinary general meeting of 21 May 2013 in Antwerp

AMSTERDAM NOTICE No. 12/04

VERSLAG VAN DE COMMISSARIS R0403 UITGIFTE VAN AANDELEN ZONDER VERMELDING VAN NOMINALE WAARDE BENEDEN FRACTIEWAARDE

VOLMACHT VOOR DE ALGEMEN VERGADERING VAN AANDEELHOUDERS VAN 12 SEPTEMBER 2012

EXPLANATORY NOTES TO THE PROPOSED AMENDMENT TO THE ARTICLES OF ASSOCIATION OF NIELSEN N.V.

VOLMACHT - POWER OF ATTORNEY

Euronext informs the members that the timetable of the corporate event will be as follows:

ABLYNX NV. (de Vennootschap of Ablynx )

OXURION. (de Vennootschap ) OPROEPING TOT BUITENGEWONE ALGEMENE VERGADERING VAN AANDEELHOUDERS

2.2 Artikel 4.2 van de Optieovereenkomst bepaalt het volgende:

Opgave 2 Geef een korte uitleg van elk van de volgende concepten: De Yield-to-Maturity of a coupon bond.

BELANGRIJK BERICHT AAN ALLE AANDEELHOUDERS

Inhoud Deze pdf bevat de volgende Engelstalige voorbeeldrapportages van sectie II, deel 3 HRA:

General info on using shopping carts with Ingenico epayments

VOLMACHT - POWER OF ATTORNEY

Volmacht Aandeelhouder Proxy Shareholder [NAAM AANDEELHOUDER] [NAME SHAREHOLDER],

2010 Integrated reporting

THROMBOGENICS. (de Vennootschap ) VOLMACHT

1 Opening. 1 Opening. 4 Appointment of the auditors. 4 Verlening opdracht aan de registeraccountant. 5 Appointment of members of the Supervisory Board

Inhoud Deze pdf bevat de volgende Engelstalige voorbeeldrapportages van sectie II, deel 3 HRA:

2019 SUNEXCHANGE USER GUIDE LAST UPDATED

THROMBOGENICS. (de Vennootschap ) VOLMACHT

POWER OF ATTORNEY GEWONE ALGEMENE VERGADERING. ANNUAL GENERAL MEETING van 25 april 2006 of 25 th April 2006

VOLMACHTFORMULIER VOOR DE BUITENGEWONE ALGEMENE VERGADERING PROXY FORM FOR THE EXTRAORDINARY SHAREHOLDERS MEETING

DE ELECTORALE RAAD VAN SINT MAARTEN,

Voorbeelden van machtigingsformulieren Nederlands Engels. Examples of authorisation forms (mandates) Dutch English. Juli 2012 Versie 2.

VOLMACHT POWER OF ATTORNEY

THROMBOGENICS. (de Vennootschap ) OPROEPING TOT BUITENGEWONE ALGEMENE VERGADERING VAN AANDEELHOUDERS

FOD VOLKSGEZONDHEID, VEILIGHEID VAN DE VOEDSELKETEN EN LEEFMILIEU 25/2/2016. Biocide CLOSED CIRCUIT

Transcriptie:

FREE TRANSLATION NYRSTAR NV Statutory auditor s Report to the extraordinary general meeting of shareholders of the company NYRSTAR NV on the proposal to approve the physically-settled conversion right attached to bonds issued by the company, with a conversion price permitting the issue of new shares below fractional value (art. 582) and on the proposal to cancel the preferential subscription right (art. 596). July 7, 2009

FREE TRANSLATION PricewaterhouseCoopers Bedrijfsrevisoren PricewaterhouseCoopers Reviseurs d'entreprises Generaal Lemanstraat 67 B-2018 Antwerpen Telephone +32 (0)3 259 3011 Facsimile +32 (0)3 259 3099 www.pwc.com STATUTORY AUDITOR S REPORT TO THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF THE COMPANY NYRSTAR NV ON THE PROPOSAL TO APPROVE THE PHYSICALLY-SETTLED CONVERSION RIGHT ATTACHED TO BONDS ISSUED BY THE COMPANY, WITH A CONVERSION PRICE PERMITTING THE ISSUE OF NEW SHARES BELOW FRACTIONAL VALUE (ART. 582) AND ON THE PROPOSAL TO CANCEL THE PREFERENTIAL SUBSCRIPTION RIGHT (ART. 596). 1. MISSION In accordance with the Articles 582 and 596 of the Belgian Company Code, we report on the proposal to approve the physically-settled conversion right attached to bonds issued by the company, with a conversion price permitting the issue of new shares below fractional value and on the proposal to cancel the preferential subscription right at NYRSTAR NV, with registered office in Balen, Zinkstraat 1, and is registered with no. 0888.728.945 in the Turnhout register of legal entities (the Company ). Extract from the Belgian Company Code, Article 582: "Wanneer de uitgifte van aandelen zonder vermelding van nominale waarden beneden de fractiewaarde van de oude aandelen van dezelfde soort op de agenda staat van een algemene vergadering, dan moet de oproeping dit uitdrukkelijk vermelden. Over de verrichting moet een omstandig verslag worden opgesteld door de raad van bestuur dat inzonderheid betrekking heeft op de uitgifteprijs en op de financiële gevolgen van de verrichting voor de aandeelhouders. Er wordt een verslag opgesteld door een commissaris of, bij diens ontstentenis, door een bedrijfsrevisor aangewezen door de raad van bestuur, of door een externe accountant aangewezen op dezelfde manier, waarin deze verklaart dat de in het verslag van de raad van bestuur opgenomen financiële en boekhoudkundige gegevens getrouw zijn en voldoende om de algemene vergadering die over het voorstel moet stemmen, voor te lichten. PricewaterhouseCoopers Bedrijfsrevisoren coöperatieve vennootschap met beperkte aansprakelijkheid, burgerlijke vennootschap met handelsvorm PricewaterhouseCoopers Reviseurs d'entreprises société coopérative à responsabilité limitée, société civile à forme commerciale Maatschappelijke zetel/siège social: Woluwe Garden, Woluwedal 18, B-1932 Sint-Stevens-Woluwe BTW/TVA BE 0429.501.944 / RPR Brussel - RPM Bruxelles / ING 310-1381195-

Die verslagen worden neergelegd op de griffie van de rechtbank van koophandel overeenkomstig artikel 75. Zij worden in de agenda vermeld. Een afschrift ervan kan worden verkregen overeenkomstig artikel 535. Het ontbreken van de verslagen bedoeld in het tweede lid heeft de nietigheid van de beslissing van de algemene vergadering tot gevolg. Extract from the Belgian Company Code, Article 596: "De algemene vergadering die moet beraadslagen en besluiten over de kapitaalverhoging, over de uitgifte van converteerbare obligaties of over de uitgifte van warrants, kan met inachtneming van de voorschriften inzake quorum en meerderheid vereist voor een statutenwijziging, in het belang van de vennootschap het voorkeurrecht beperken en opheffen. Het voorstel daartoe moet speciaal in de oproeping worden vermeld. De raad van bestuur verantwoordt zijn voorstel in een omstandig verslag, dat inzonderheid betrekking heeft op de uitgifteprijs en op de financiële gevolgen van de verrichting voor de aandeelhouders. Er wordt een verslag opgesteld door de commissaris-revisor of, bij diens ontstentenis, door een bedrijfsrevisor aangewezen overeenkomstig artikel 34 2,, waarin deze verklaart dat de in het verslag van de raad van bestuur opgenomen financiële en boekhoudkundige gegevens getrouw zijn en voldoende om de algemene vergadering die over het voorstel moet stemmen, voor te lichten. Die verslagen worden neergelegd op de griffie van de rechtbank van koophandel overeenkomstig artikel 75. Our responsibility is to express our opinion on: - the identification of the transaction - the adequacy of the information included in the special report of the board of directors on the proposal to approve the physically-settled conversion right attached to bonds issued by the company, with a conversion price permitting the issue of new shares below fractional value and on the proposal to cancel the preferential subscription right. We conducted our mission in accordance with the legal requirements as issued by the "Institut des Reviseurs d'entreprises/instituut der Bedrijfsrevisoren" and entails a review of the special report of the board of directors in relation to the possible issuance price of the new shares that will be created in view of the proposed transaction and the financial consequences of the transaction for the shareholders. Furthermore information was gathered as deemed necessary in view of the mission. 2

2. PROPOSED TRANSACTION In its special report dated 2 July 2009, the board of directors of the Company, resolved that it will issue bonds for an aggregate principal amount of EUR 105 million, which can be increased with a principal amount of up to EUR 15 million depending on the exercise of an over-allotment option that has been granted within the context of the placement of the bonds and which can be exercised until 7 July 2009. The bonds are intended to be convertible into existing or new shares of the Company. The physically-settled conversion right in respect of new shares attached to the bonds needs to be approved by the extraordinary general shareholders meeting of the Company. The shares to be issued upon conversion of the bonds will have the same rights and benefits as, and rank pari passu in all respects with the existing and outstanding shares of the Company at the moment of issuance and will participate in the results of the Company not yet allocated at the moment of conversion. For further information on the terms and conditions of the bonds, reference is made to the terms and conditions attached to the aforementioned special report of the board of directors. The company s current share capital amounts to EUR 1,490,760,008.09 represented by 100,000,000 shares without nominal value, being a fractional value of EUR 14.91 per share. The conversion price, being the price to convert the bonds in new shares is EUR 7.6203 per share. It should be noted that the initial conversion price of EUR 7.6203 is set at a premium of 27.5% to the volume weighted average price of the Company s ordinary share on Euronext Brussels from launch to pricing on the day the bonds were placed, on the 2 July 2009. In other words, the conversion price includes a premium to the market price of the Company s shares at the time of the placement of the bonds. The conversion price of EUR 7.6203 is less than the current fractional value of the Company s shares (which amounts to rounded EUR 14.91 per share). The conversion price is less than the current fractional value of the Company s shares because it has been determined with reference to the trading price of the Company s shares prior to the offering, which is currently lower than the fractional value. In connection with the proposal to approve the conversion right attached to the bonds, it is proposed that, as far as necessary and applicable, the preferential subscription right of the shareholders be cancelled for the benefit of the bondholders. The adequacy of the information provided by the board of directors as well as the consequences of the possible conversion of all bonds into new shares is explained below. 3

3. ADEQUACY OF THE INFORMATION PROVIDED BY THE BOARD OF DIRECTORS AND THE FINANCIAL CONSEQUENCES OF THE POSSIBLE CONVERSION OF ALL BONDS INTO NEW SHARES. Upon conversion of the bonds into new shares, the company will have to issue new shares, and the share capital of the company will be increased. Accordingly, summarized and for illustration purposes only, if and to the extent the full principal amount of the bonds of EUR 105 million were to be converted on the date hereof (not including the bonds for a maximum principal amount of EUR 15 million that could still be issued if the over-allotment option is exercised, if at all), the Company would have to issue 13.778.998 new shares, assuming that the aggregate amount to be converted would amount to EUR 105 million and that the applicable conversion price would amount to EUR 7.6203 per share. If the over-allotment option is exercised with respect to bonds for a maximum principal amount of EUR 15 million, the full principal amount of all bonds would be EUR 120 million, and upon conversion of these bonds on the date hereof, the Company would have to issue 15,747,426 new shares in total based on the aforementioned conversion price. Consequences of the transaction on the share capital Should all bonds (including the exercise in full of the over-allotment option) be converted in new shares on the date of the special report of the board of directors at a conversion price of EUR 7.6203, the share capital would be increased as follows: Capital increase EUR 120,000,000 : 7.6203 * = 15,747,426 shares. * conversion price (rounded) Such capital increase of EUR 120,000,000 million would result in the creation of 15,747,426 new shares without nominal value, each issued at a price of EUR 7.6203 which is below the fractional value of the old shares: Amountl % Capital Fractional value Old shares 100.000.000 86,4 1.490.760.008,09 14,91 New shares 15.747.426 13,6 120.000.000,00 7,62 Total number of shares 115.747.426 100 1.610.760.008,09 13,92 after capital increase The above calculation reveals that the current share capital of the existing shareholders is diluted by 13.6%. 4

Consequences of the transaction on equity CONSOLIDATED EQUITY based on the audited 31/12/2008 IFRS financial statements (not taking into account the result of 2009) Before the transaction the consolidated equity amounts to: EUR million Equity as per 31 December 2008 711.10 Calculated book value per share: EUR 711.10 million / 100,000,000 shares = EUR 7.11 per share. After the transaction the consolidated equity amounts to EUR 831.10, calculated as follows: EUR million Equity as per 31 December 2008 711.10 Conversion of all bonds on the date of the special report of the board of directors 120.00 Total 831.10 Calculated book value per share: EUR 831.10 million / 115,747,427 = EUR 7.18 per share. 5

NON-CONSOLIDATED EQUITY based on the audited 31/12/2008 statutory accounts (not taking into account the result of 2009) Before the transaction the non-consolidated equity amounts to: EUR Equity as per 31 December 2008 1,494,531,722 Calculated book value per share: EUR 1,494,531,722 / 100,000,000 shares = EUR 14.95 per share. After the transaction the non-consolidated equity amounts to EUR 1,614,531,722, calculated as follows: EUR Equity as per 31 December 2008 1,494,531,722 Conversion of all bonds on the date of the special report of the board of directors 120,000,000 Total 1,614,531,722 Calculated book value per share: EUR 1,614,531,722 / 115,747,426 shares = EUR 13.95 per share. As indicated above, the conversion price of the bonds is higher, respectively lower than the accounting net equity per-share based on the aforementioned consolidated financial statements and non-consolidated financial statements of the Company for the financial year ended 31 December 2008. Accordingly, in the event the bonds were to be converted, this would entail, from an accounting perspective, an accretion, respectively a dilution, of the accounting net equity per share, based on the consolidated financial statements and the non-consolidated financial statements of the Company for the financial year ended on 31 December 2008. Whether the same effect would also apply based on future financial statements of the company will depend on the company s accounting net equity position at the time of conversion. 6

The information as recorded in the special report of the board of directors is in accordance with the Articles 582 and 596 of the Belgian Company Code. Based on our procedures carried out we conclude that the special report provides sufficient information towards the general shareholders meeting in order to come to a fair conclusion in respect of the proposed transaction. 7

4. CONCLUSION Based on our review we conclude that: - the board of directors comply with the regulations set forth in Articles 582 and 596 of the Belgian Company Code; - the proposal on the physically-settled conversion right attached to bonds issued by the company, with a conversion right permitting the issue of new shares below fractional value and on the proposal to cancel the preferential subscription right, has been properly supported in a special report of the board of directors, in which the issuance price and the financial consequences for the shareholders have been properly disclosed. - in the special report of the board of directors the disclosed financial information is fair and sufficient in order for the general shareholders meeting to decide upon the transaction. This report only comprehends the requirements of Articles 582 and 596 of the Belgian Company Code and is not intended for use in any other context. Antwerp, July 7, 2009 PricewaterhouseCoopers Bedrijfsrevisoren, Represented by Peter Van den Eynde, Bedrijfsrevisor 8